港股异动 | 君实生物(01877)现跌超5% Coherus终止重组人源化TIGIT单克隆抗体许可合作
君实生物(01877)现跌超5%，截至发稿，跌5.46%，报16.98港元，成交额977.83万港元。
消息面上，1月11日，君实生物发布公告表示，已收到Coherus关于终止重组人源化TIGIT单克隆抗体（项目代号：JS006）许可合作的通知函。许可终止生效后，Coherus不再享有JS006的许可权利，君实生物重新获得开发、生产和商业化JS006的全部全球权利。
据悉，Coherus宣布对其产品管线进行优先级整理，认为终止TIGIT项目的合作符合其最大利益。君实生物在公告中表示，此次终止不会影响公司前期已从Coherus处收到的3500万美元执行费Coherus承担的研发费用等，根据许可与商业化协议，上述款项不予退回。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.